Repligen Corporation (RGEN)
After hours:
| Previous close | 162.40 |
| Open | 162.19 |
| Bid | 120.00 x 900 |
| Ask | 199.68 x 800 |
| Day's range | 161.92 - 166.81 |
| 52-week range | 137.21 - 327.32 |
| Volume | |
| Avg. volume | 545,604 |
| Market cap | 9.231B |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | 64.29 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors
WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and bioprocessing industry expert. Dr. Konstantinov brings to the director role nearly 30 years of relevant experience, including his current position as Chief Technology Officer at Codiak BioSciences, where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences. D
- GlobeNewswire
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at three upcoming investor conferences. Craig-Hallum’s 19th Annual Institutional Investor conference being held June 1. Management will be hosting one-on-one meetings with investors who are registered to attend the conference.William Blair’s 42nd Annual Growth Stock Conference being held in Chica
- GlobeNewswire
Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base business growth of 37% —Growth driven by combination of base business strength, COVID-related demand, and acquisition revenue WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results f
